instruction stringclasses 1
value | input stringlengths 6 390 | output stringlengths 3 125 ⌀ |
|---|---|---|
Identify drugs from the given text | When Is Stereotactic Ablative Body Radiotherapy an Option? | null |
Identify drugs from the given text | Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer. | Dostarlimab |
Identify drugs from the given text | Cost-Effectiveness Analysis Of Endoscopic Sleeve Gastroplasty Compared To Semaglutide For Weight Loss In Patients With Obesity | Semaglutide |
Identify drugs from the given text | Chloroquine inhibited Rab11 mediated E-cadherin transport in collective colon cell migration in Dasatinib resistant cells | Chloroquine |
Identify drugs from the given text | Clinical update of a plant-derived COVID VLP vaccine candidate | COVID VLP Vaccine |
Identify drugs from the given text | A phase Ib trial of alpelisib and weekly cisplatin in patients with solid tumor malignancies. | Alpelisib;;Cisplatin |
Identify drugs from the given text | A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer | 68Ga-ABY-025 |
Identify drugs from the given text | Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort. | null |
Identify drugs from the given text | Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial | Apatinib;;Camrelizumab |
Identify drugs from the given text | A phase II trial of pembrolizumab and poly-ICLC in patients with metastatic mismatch repair-proficient colon cancer. | Pembrolizumab;;Poly ICLC |
Identify drugs from the given text | De-Escalation Of Bone-Targeted Treatment: Does The Number Of 6-Monthly Adjuvant Zoledronate Infusions Received Affect Treatment Efficacy For Early Breast Cancer? A Sub-Study Of Abcsg-12 | Zoledronate |
Identify drugs from the given text | Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas | HMBD-001 |
Identify drugs from the given text | Anti-PR3 Positive Pauci-Immune Glomerulonephritis Associated With Immune Checkpoint Inhibitor Therapy and Responsive to Corticosteroid and Rituximab | Rituximab |
Identify drugs from the given text | BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. | Nemtabrutinib |
Identify drugs from the given text | Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis. | Buparlisib;;Paclitaxel |
Identify drugs from the given text | Treatment trends and prognostic factors related to histology of squamous cell carcinoma of the prostate: A SEER review. | null |
Identify drugs from the given text | CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)-A phase IIa study. | CVM-1118 |
Identify drugs from the given text | Two Decades of Progress in EGFR-Mutated Non-Small Cell Lung Cancer | null |
Identify drugs from the given text | Combining Pharmacotherapy of BI 425809 with Computerized Cognitive Training in Patients with Schizophrenia: Baseline Data and Patient Demographics from an Ongoing Phase II Trial | BI-425809 |
Identify drugs from the given text | AKI in Patients With Leukemia Submitted to Allogeneic Hematopoietic Stem Cell Transplant: A Cohort Analysis | Allogeneic Hematopoietic Stem Cell |
Identify drugs from the given text | Bortezomib Maintenance After Upfront Allogeneic Transplantation In Myeloma Patients: Less Chronic Gvhd And Immunosuppression But Still No Impact On Survival | Bortezomib |
Identify drugs from the given text | Clinical utility of interim CT scans in patients receiving bendamustine and rituximab for first line treatment of follicular lymphoma. | Bendamustine;;Rituximab |
Identify drugs from the given text | Watching or Waiting After Complete Response to Total Neoadjuvant Therapy: No Doubt About It | null |
Identify drugs from the given text | BG34-200 immunotherapy of advanced melanoma | BG34-200 |
Identify drugs from the given text | CORE1: Phase 2 Single arm study of CG0070 combined with Pembrolizumab in patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) | CG-0070;;Pembrolizumab |
Identify drugs from the given text | A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) | Ibrutinib;;Pevonedistat |
Identify drugs from the given text | BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC | BDTX-1535 |
Identify drugs from the given text | Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase III trial. | Capecitabine |
Identify drugs from the given text | Cd20 Car-T Therapy With Mb-106 For Btk Inhibitor-Refractory Waldenstrom Macroglobulinemia (Wm)/ Lymphoplasmacytic Lymphoma (Lpl) - Single Institution Study | Cd\D20 Car-T Cell;;MB-106 |
Identify drugs from the given text | Advanced Chronic Myelomonocytic Leukemia In Elderly And Frail Patients Managed By Azacitidine In The Field Of Clinical Practice. | Azacitidine |
Identify drugs from the given text | A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine | BNT162b2 |
Identify drugs from the given text | Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. | Daratumumab;;Dexamethasone;;Lenalidomide;;Bortezomib;;Dexamethasone;;Lenalidomide |
Identify drugs from the given text | CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma | Ciltacabtagene Autoleucel |
Identify drugs from the given text | A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP). | Niraparib |
Identify drugs from the given text | Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients | SARS-CoV-2 mRNA Vaccine |
Identify drugs from the given text | Differential responses and mechanisms of resistance to cediranib in high grade serous ovarian cancer mouse models | Cediranib |
Identify drugs from the given text | Antiproliferative activity of EC359, an inhibitor of leukemia inhibitory factor receptor (LIF-R), singly and in combination with chemotherapy drugs against pancreatic cancer cell lines | EC359 |
Identify drugs from the given text | A Randomised Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First or Second Line Chemotherapy (NIVORAD) | Nivolumab |
Identify drugs from the given text | Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP). | Abiraterone Acetate;;Apalutamide;;Prednisone |
Identify drugs from the given text | A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma | Allogeneic Stem Cell |
Identify drugs from the given text | Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with nonmetastatic muscle invasive bladder cancer (NMMIBC) | Avelumab |
Identify drugs from the given text | Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era | Rituximab |
Identify drugs from the given text | Thrombotic Events In Children With Acute Lymphoblastic Leukemia: Experience Of Italian Aieop Centers (2009-2017) | null |
Identify drugs from the given text | A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. | Vinorelbine |
Identify drugs from the given text | Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence. | Radium-223 |
Identify drugs from the given text | BATF and IRF4 cooperate to counter exhaustion in tumour-infiltrating CAR T cells | CAR T-cell |
Identify drugs from the given text | Activation of human skin mast cells by vancomycin via MrgX2: Comparison to the effects of brimonidine | Vancomycin;;Brimonidine |
Identify drugs from the given text | Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL) | Copanlisib;;Rituximab |
Identify drugs from the given text | ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts | Antithymocyte Globulin;;Cyclophosphamide |
Identify drugs from the given text | Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling. | ADG126 |
Identify drugs from the given text | Azd7798:A New Ccr9 Depleting Antibody To Treat Crohn'S Disease | Azd7798 |
Identify drugs from the given text | Determining efficacy of combining the MEK inhibitor trametinib with vincristine identified by unbiased high throughput screening in RAS-mutated colorectal cancer cells | Trametinib;;Vincristine |
Identify drugs from the given text | A Prospective Study to Assess Safety and Efficacy of Bone-Marrow Derived Mesenchymal Stromal Cells for Severe Frequently Relapsing or Steroid-Dependent Idiopathic Nephrotic Syndrome: The MESNEPH Study | Mesenchymal Stromal Cell |
Identify drugs from the given text | A Phase 2 Study Of Bezuclastinib (Cgt9486), A Novel, Highly Selective, Potent Kit D816V Inhibitor, In Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, And Early Insights | Bezuclastinib |
Identify drugs from the given text | AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion | AMB302/GR1017 |
Identify drugs from the given text | Deep Vein Thrombosis after COVID-19 Vaccinations | COVID-19 Vaccine |
Identify drugs from the given text | The Swallowing Assessment In Disorders Of Consciousness (Swadoc) Validation: A Multicenter Prospective Cohort Study | null |
Identify drugs from the given text | Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) | Ipilimumab;;Nivolumab;;Sunitinib |
Identify drugs from the given text | Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15TM) eradicate tumors in a melanoma PDX model through recognition of shared tumor antigens | cytoTIL15 |
Identify drugs from the given text | A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study. | 5-Fluorouracil;;Liposomal Irinotecan;;Oxaliplatin |
Identify drugs from the given text | Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | CB-668 |
Identify drugs from the given text | COVID-19 Vaccination in Adults with Immune Thrombocytopenia (ITP): Data from the Platelet Disorder Support Association (PDSA) Patient Registry | COVID-19 Vaccine |
Identify drugs from the given text | CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts | RVU120 |
Identify drugs from the given text | Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC | BAY-2402234 |
Identify drugs from the given text | A Phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results | Cemiplimab;;REGN7075 |
Identify drugs from the given text | Acalabrutinib In The Treatment Of Richter Syndrome | Acalabrutinib |
Identify drugs from the given text | Case report: dramatic response to Crizotinib in a patient with synchronous multiple primary lung cancer positive for a novel ARL1-MET fusion | Crizotinib |
Identify drugs from the given text | Adding dosing of plasmid encoding p62/SQSTM1 to Gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer. | Gemcitabine |
Identify drugs from the given text | Comparison of different treatment modalities for favorable risk acute myeloid leukemia: Standard-dose anthracycline versus high-dose anthracycline versus addition of gemtuzumab ozogamicin. | Gemtuzumab Ozogamicin |
Identify drugs from the given text | A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission | 5-Azacytidine;;Venetoclax |
Identify drugs from the given text | Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma | Tebentafusp |
Identify drugs from the given text | B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies | Vemurafenib;;Carboplatin;;Crizotinib;;Everolimus;;Paclitaxel;;Sorafenib |
Identify drugs from the given text | A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma. | Avelumab;;DCC-3014 |
Identify drugs from the given text | CB-1 receptor agonist CP-55,940 drastically increases spindling activity and transition time between NREM and REM sleep | CP-55,940 |
Identify drugs from the given text | Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Adult Onset Leukoencephalopathy With Axonal Spheroids | Hematopoietic stem-cell transplantation |
Identify drugs from the given text | Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Allogeneic Hematopoietic Cell |
Identify drugs from the given text | Analysis of 53 Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated with CD7-Targeted CAR-T Cell Therapy | CD7-Targeted CAR-T Cell |
Identify drugs from the given text | A new role of transcription-coupled DNA repair in affecting temozolomide adducts and mutations | Temozolomide |
Identify drugs from the given text | Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study | Luspatercept |
Identify drugs from the given text | Combined Treatment With Venetoclax Plus Hypomethylating Agent Or Cytarabine Versus Treatment With Hypomethylating Agent Alone In Acute Myeloid Leukemia In Poor Prognosis Patients. | Cytarabine;;Venetoclax |
Identify drugs from the given text | Bendamustine Immediately Before Mobilization May Difficult The Collection Of Hematopoietic Stem Cells In Lymphoma. | Bendamustine |
Identify drugs from the given text | A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC). | Bevacizumab;;FOLFIRI;;Onvansertib |
Identify drugs from the given text | A Prospective Study of Camrelizumab monotherapy following definitiveconcurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer | Camrelizumab |
Identify drugs from the given text | A new risk calculator to predict changes in International Prostate Symptom Score and risk of retention or surgery in Benign Prostatic Hyperplasia patients with moderate-severe symptoms at risk of disease progression receiving placebo, dutasteride, tamsulosin, or combination therapy. | Dutasteride;;Tamsulosin |
Identify drugs from the given text | Cctg Ind.236: A Phase 1B Trial Of Combined Cfi-402257 And Weekly Paclitaxel In Patients With Her2-Negative (Her2-) Advanced Breast Cancer (Abc) | CFI-402257;;Paclitaxel |
Identify drugs from the given text | Cannabidiol as a potential therapeutic agent for memory impairment – experimental study | Cannabidiol |
Identify drugs from the given text | A phase II study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer | Anlotinib;;Toripalimab |
Identify drugs from the given text | Clinical Activity of Nivolumab in Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Kidney Cancer | Nivolumab |
Identify drugs from the given text | Clinical Evaluation Of Rituximab Treatment Experience In Myathenia Gravis. | Rituximab |
Identify drugs from the given text | A phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor | surufatinib;;toripalimab |
Identify drugs from the given text | A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). | Lenvatinib;;toripalimab |
Identify drugs from the given text | Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA). | Docetaxel;;Trastuzumab |
Identify drugs from the given text | Cardiac Effects of Lamotrigine in a Veteran Population | Lamotrigine |
Identify drugs from the given text | A Phase 1b Study of a Single Priming Dose of 177Lu-PSMA-617 Coupled with Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) | 177Lu-PSMA-617;;Pembrolizumab |
Identify drugs from the given text | ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages | ATYR-2810 |
Identify drugs from the given text | Comparative Analysis of Clinical Results of Compared With TPF Induction of Chemotherapy and PF Adjuvant Chemotherapy Combined With Cisplatin Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma | Cisplatin |
Identify drugs from the given text | Development of IMGS-001, a novel anti-PD-L1/PD-L2 dual specific, multi-functional antibody, to treat immune excluded tumors | IMGS-001 |
Identify drugs from the given text | Combination vaccine, adoptive NK cell transfer and checkpoint blockade reduce murine neuroblastoma progression after bone marrow transplant | NK Cell |
Identify drugs from the given text | Combination Of Bcl-2 Inhibitor, Hypomethylation Agents And Low-Dose Cytarabine As A Salvage Therapy For Acute Myeloid Leukemia And Myelodysplastic Syndromes | Cytarabine |
Identify drugs from the given text | Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma | CAR-T Cell |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 75